Metabolic syndrome

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5.[Abstract][Full Text]

2. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007 Nov;91(6):1169-84.[Abstract]

3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.[Abstract][Full Text]

4. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008 Dec;29(7):777-822.[Abstract]

5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.[Abstract][Full Text]

6. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al; MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab. 2005 Jul;7(4):397-405.[Abstract]

7. Athyros VG, Ganotakis ES, Elisaf M, et al. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin. 2005 Aug;21(8):1157-9.[Abstract]

8. O'Hearn M, Lauren BN, Wong JB, et al. Trends and disparities in cardiometabolic health among U.S. adults, 1999-2018. J Am Coll Cardiol. 2022 Jul 12;80(2):138-51.[Abstract]

9. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S9-30.[Abstract]

10. Wu CC, Yeh WT, Crow RS, et al. Comparison of electrocardiographic findings and associated risk factors between Taiwan Chinese and US White adults. Int J Cardiol. 2008 Aug 18;128(2):224-31.[Abstract]

11. Sheth T, Nair C, Nargundkar M, et al. Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ. 1999 Jul 27;161(2):132-8.[Abstract][Full Text]

12. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002 Jul 16;106(3):286-8.[Abstract]

13. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007 Feb;92(2):399-404.[Abstract][Full Text]

14. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004 Feb 3;109(4):551-6.[Abstract][Full Text]

15. Walker BR. Cortisol: cause and cure for metabolic syndrome? Diabet Med. 2006 Dec;23(12):1281-8.[Abstract]

16. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med. 2001 Dec 13;345(24):1772-4.[Abstract]

17. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000 Jul;106(2):171-6.[Abstract][Full Text]

18. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans: implications for the insulin-resistant state. Diabetes Care. 2000 Jul;106(2):171-6.[Abstract]

19. Sandhofer A, Kaser S, Ritsch A, et al. Cholesteryl ester transfer protein in metabolic syndrome. Obesity (Silver Spring). 2006 May;14(5):812-8.[Abstract][Full Text]

20. Wang H, Knaub LA, Jensen DR, et al. Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes. 2009 Jan;58(1):116-24.[Abstract][Full Text]

21. Preiss-Landl K, Zimmermann R, Hammerle G, et al. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol. 2002 Oct;13(5):471-81.[Abstract]

22. Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets. 2007 Feb;11(2):191-205.[Abstract]

23. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):525-46.[Abstract]

24. Papadopoulos DP, Perrea D, Thomopoulos C, et al. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. J Clin Hypertens (Greenwich). 2009 Feb;11(2):61-5.[Abstract]

25. Deepa R, Velmurugan K, Arvind K, et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance: the Chennai Urban Rural Epidemiology Study (CURES). Metabolism. 2006 Sep;55(9):1232-8.[Abstract]

26. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004 Feb;30(1):13-9.[Abstract]

27. Inadera H. The usefulness of circulating adipokine levels for the assessment of obesity-related health problems. Int J Med Sci. 2008 Aug 29;5(5):248-62.[Abstract][Full Text]

28. Kakafika AI, Liberopoulos EN, Karagiannis A, et al. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol. 2006 Jul;4(3):175-83.[Abstract]

29. Bellia C, Bivona G, Scazzone C, et al. Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease. Ther Clin Risk Manag. 2007 Dec;3(6):999-1001.[Abstract][Full Text]

30. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008 Aug 11;168(15):1609-16.[Abstract]

31. Lassale C, Tzoulaki I, Mooons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018 Feb 1;39(5):397-406.[Abstract][Full Text]

32. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003 Feb 24;163(4):427-36.[Abstract][Full Text]

33. Bianchi G, Rossi V, Muscari A, et al. Physical activity is negatively associated with the metabolic syndrome in the elderly. QJM. 2008 Sep;101(9):713-21.[Abstract]

34. Edwardson CL, Gorely T, Davies MJ, et al. Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One. 2012;7(4):e34916.[Abstract][Full Text]

35. Yung LM, Laher I, Yao X, et al. Exercise, vascular wall and cardiovascular diseases: an update (part 2). Sports Med. 2009;39(1):45-63.[Abstract]

36. Parker DR, Weiss ST, Troisi R, et al. Relationship of dietary saturated fatty acids and body habitus to serum insulin concentrations: the Normative Aging Study. Am J Clin Nutr. 1993 Aug;58(2):129-36.[Abstract]

37. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997 Nov 20;337(21):1491-9.[Abstract][Full Text]

38. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation. 2008 Feb 12;117(6):754-61.[Abstract][Full Text]

39. Baik I, Shin C. Prospective study of alcohol consumption and metabolic syndrome. Am J Clin Nutr. 2008 May;87(5):1455-63.[Abstract][Full Text]

40. Pankow JS, Jacobs DR Jr, Steinberger J, et al. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care. 2004 Mar;27(3):775-80.[Abstract][Full Text]

41. Panhuysen CI, Cupples LA, Wilson PW, et al. A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study. Diabetologia. 2003 Apr;46(4):579-87.[Abstract][Full Text]

42. Wang H, Dong S, Xu H, et al. Genetic variants in FTO associated with metabolic syndrome: a meta- and gene-based analysis. Mol Biol Rep. 2012 May;39(5):5691-8.[Abstract][Full Text]

43. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003 Jun;24(3):302-12.[Abstract][Full Text]

44. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006 Mar;29(3):270-80.[Abstract]

45. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):48-53.[Abstract][Full Text]

46. Ketel IJ, Stehouwer CD, Serne EH, et al. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab. 2008 Sep;93(9):3365-72.[Abstract]

47. Dimopoulou C, Goulis DG, Corona G, et al. The complex association between metabolic syndrome and male hypogonadism. Metabolism. 2018 Sep;86:61-8.[Abstract]

48. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011 Jan;8(1):272-83.[Abstract]

49. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012 Jan;35(1):104-20.[Abstract]

50. Anagnostis P, Lambrinoudaki I, Stevenson JC, et al. Menopause-associated risk of cardiovascular disease. Endocr Connect. 2022 Apr 22;11(4):e210537.[Abstract][Full Text]

51. Sen Y, Aygun D, Yilmaz E, et al. Children and adolescents with obesity and the metabolic syndrome have high circulating cortisol levels. Neuro Endocrinol Lett. 2008 Feb;29(1):141-5.[Abstract]

52. Duclos M, Marquez Pereira P, Barat P, et al. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res. 2005 Jul;13(7):1157-66.[Abstract][Full Text]

53. Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006 Jul;163(7):1273-6.[Abstract][Full Text]

54. Chasens ER, Imes CC, Kariuki JK, et al. Sleep and Metabolic Syndrome. Nurs Clin North Am. 2021 Jun;56(2):203-17.[Abstract][Full Text]

55. Kim DH, Kim B, Han K, et al. The relationship between metabolic syndrome and obstructive sleep apnea syndrome: a nationwide population-based study. Sci Rep. 2021 Apr 22;11(1):8751.[Abstract][Full Text]

56. Song SO, He K, Narla RR, et al. Metabolic consequences of obstructive sleep apnea especially pertaining to diabetes mellitus and insulin sensitivity. Diabetes Metab J. 2019 Apr;43(2):144-55.[Abstract][Full Text]

57. Zhang Y, Jiang X, Liu J, et al. The association between insomnia and the risk of metabolic syndrome: A systematic review and meta-analysis. J Clin Neurosci. 2021 Jul;89:430-6.[Abstract][Full Text]

58. Smiley A, King D, Bidulescu A. The Association between sleep duration and metabolic syndrome: The NHANES 2013/2014. Nutrients. 2019 Oct 26;11(11):2582.[Abstract][Full Text]

59. Aboud M, Elgalib A, Kulasegaram R, et al. Insulin resistance and HIV infection: a review. Int J Clin Pract. 2007 Mar;61(3):463-72.[Abstract]

60. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004 Sep 22;292(12):1440-6.[Abstract][Full Text]

61. Barone Gibbs B, Hivert MF, Jerome GJ, et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how?: a scientific statement from the American Heart Association. Hypertension. 2021 Aug;78(2):e26-37.[Abstract][Full Text]

62. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021 Dec 7:144(23): e472-87.[Abstract][Full Text]

63. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022 Aug 2;146(5):e18-43.[Abstract][Full Text]

64. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report ofthe American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10): e177-232.[Abstract][Full Text]

65. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-337.[Abstract][Full Text]

66. Romero-Cabrera JL, García-Ríos A, Sotos-Prieto M, et al. Adherence to a mediterranean lifestyle improves metabolic status in coronary heart disease patients: a prospective analysis from the CORDIOPREV study. J Intern Med. 2023 May;293(5):574-88.[Abstract][Full Text]

67. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: behavioral counseling interventions. Nov 2020 [internet publication].[Full Text]

68. ​US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: behavioral counseling interventions. Jul 2022 [internet publication].​[Full Text]

69. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006 Jun;83(6):1237-47.[Abstract][Full Text]

70. Nagahama K, Inoue T, Kohagura K, et al. Hyperuricemia predicts future metabolic syndrome: a 4-year follow-up study of a large screened cohort in Okinawa, Japan. Hypertens Res. 2014 Mar;37(3):232-8.[Abstract]

71. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-73.[Abstract][Full Text]

72. Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006 Mar;91(3):786-9.[Abstract][Full Text]

73. Castaneda A, Jauregui-Maldonado E, Ratnani I, et al. Correlation between metabolic syndrome and sleep apnea. World J Diabetes. 2018 Apr 15;9(4):66-71.[Abstract][Full Text]

74. Shu J, Zhao R, Xu H, et al. Hyperuricemia is associated with metabolic syndrome: A cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES). Prev Med Rep. 2023 Dec;36:102520.[Abstract][Full Text]

75. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40.[Abstract][Full Text]

76. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann N Y Acad Sci. 2006 Nov;1083:37-53.[Abstract]

77. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999. [Full Text]

78. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999 May;16(5):442-3.[Abstract]

79. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun;9(3):237-52.[Abstract]

80. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. Diabet Med. 2006 May;23(5):469-80.[Abstract]

81. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52.[Abstract][Full Text]

82. American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan;47(Suppl_1):S1-321.​[Full Text]

83. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010.[Abstract][Full Text]

84. Ilanne-Parikka P, Eriksson JG, Lindström J, et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care. 2008 Apr;31(4):805-7.[Abstract][Full Text]

85. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 Jan 27;109(3):433-8.[Abstract][Full Text]

86. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002 Jan;25(1):202-12.[Abstract][Full Text]

87. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens. 2001 Jun;19(6):1053-60.[Abstract]

88. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006 Feb;47(2):296-308.[Abstract][Full Text]

89. Chen J, Gu D, Huang J, et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009 Mar 7;373(9666):829-35.[Abstract]

90. Hooper L, Abdelhamid A, Bunn D, et al. Effects of total fat intake on body weight. Cochrane Database Syst Rev. 2015 Aug 7;(8):CD011834.[Abstract][Full Text]

91. Hartley L, May MD, Loveman E, et al. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2016 Jan 7;2016(1):CD011472.[Abstract][Full Text]

92. Harber MP, Schenk S, Barkan AL, et al. Alterations in carbohydrate metabolism in response to short-term dietary carbohydrate restriction. Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E306-12.[Abstract][Full Text]

93. Halton TL, Willett WC, Liu S, et al. Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med. 2006 Nov 9;355(19):1991-2002.[Abstract][Full Text]

94. Salas-Salvadó J, Bulló M, Estruch R, et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med. 2014 Jan 7;160(1):1-10.[Abstract]

95. Reimer RA, Yamaguchi H, Eller LK, et al. Changes in visceral adiposity and serum cholesterol with a novel viscous polysaccharide in Japanese adults with abdominal obesity. Obesity (Silver Spring). 2013 Sep;21(9):E379-87.[Abstract][Full Text]

96. Klemsdal TO, Holme I, Nerland H, et al. Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2010 Mar;20(3):195-201.[Abstract]

97. Hu T, Mills KT, Yao L, et al. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol. 2012 Oct 1;176 Suppl 7(Suppl 7):S44-54.[Abstract]

98. Bray GA. Fructose and risk of cardiometabolic disease. Curr Atheroscler Rep. 2012 Dec;14(6):570-8.[Abstract]

99. Bassi N, Karagodin I, Wang S, et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med. 2014 Dec;127(12):1242.e1-10.[Abstract]

100. Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the community preventive services task force. Ann Intern Med. 2015 Sep 15;163(6):437-51.[Abstract][Full Text]

101. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002 Feb 21;346(8):591-602.[Abstract]

102. Thompson PD, Buchner D, Piña IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003 Jun 24;107(24):3109-16.[Abstract][Full Text]

103. Hordern MD, Dunstan DW, Prins JB, et al. Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from Exercise and Sport Science Australia. J Sci Med Sport. 2012 Jan;15(1):25-31.[Abstract]

104. Li R, Qu S, Zhang P, et al. Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015 Sep 15;163(6):452-60.[Abstract][Full Text]

105. Haufe S, Kerling A, Protte G, et al. Telemonitoring-supported exercise training, metabolic syndrome severity, and work ability in company employees: a randomised controlled trial. Lancet Public Health. 2019 Jul;4(7):e343-52.[Abstract][Full Text]

106. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014 Jun 24;129(25 suppl 2):S102-38.[Abstract][Full Text]

107. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endor Pract. 2016 Jul;22 Suppl 3:1-203.[Abstract][Full Text]

108. Mares AC, Chatterjee S, Mukherjee D. Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. Curr Opin Cardiol. 2022 Jul 1;37(4):350-5.[Abstract][Full Text]

109. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.[Abstract][Full Text]

110. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021 Apr 13;325(14):1414-25.[Abstract][Full Text]

111. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical Trial. JAMA. 2021 Apr 13;325(14):1403-13.[Abstract][Full Text]

112. Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 Feb;25(2):468-78.[Abstract][Full Text]

113. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-32.[Abstract][Full Text]

114. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 16;377(9774):1341-52.[Abstract]

115. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb;20(2):330-42.[Abstract][Full Text]

116. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb;95(2):297-308.[Abstract][Full Text]

117. Lei XG, Ruan JQ, Lai C, et al. Efficacy and safety of phentermine/ topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021 Jun;29(6):985-94.[Abstract]

118. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20;281(3):235-42.[Abstract][Full Text]

119. Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin. 2004 Sep;20(9):1393-401.[Abstract]

120. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61.[Abstract][Full Text]

121. Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40-66.[Abstract][Full Text]

122. NIH Consensus Development Conference Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991 Dec 15;115(12):956-61.[Abstract]

123. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004 Oct 13;292(14):1724-37.[Abstract]

124. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-52.[Abstract][Full Text]

125. Athyros VG, Tziomalos K, Karagiannis A, et al. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev. 2011 Jul;12(7):515-24.[Abstract][Full Text]

126. Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011. Obes Surg. 2012 May;22(5):677-84.[Abstract]

127. Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). 2013 Aug;21(8):1561-70.[Abstract]

128. Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab. 2014 Aug;16(8):719-27.[Abstract]

129. US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: preventive medication. Apr 2022 [internet publication].[Full Text]

130. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.[Abstract][Full Text]

131. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.[Abstract][Full Text]

132. Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis. 2007 Oct;1(1):7-26.[Abstract]

133. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab. 2008 Dec;10(12):1204-11.[Abstract]

134. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279-89.[Abstract]

135. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.[Abstract][Full Text]

136. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009 Jan;52(1):17-30.[Abstract]

137. Athyros VG, Elisaf MS, Alexandrides T, et al. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology. 2012 Jul;63(5):358-66.[Abstract]

138. Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol. 2011 Nov;9(6):647-57.[Abstract]

139. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.[Abstract][Full Text]

140. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.[Abstract][Full Text]

141. Zhao XQ, Krasuski RA, Baer J, et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am J Cardiol. 2009 Dec 1;104(11):1457-64.[Abstract]

142. Krysiak R, Gdula-Dymek A, Bachowski R, et al. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care. 2010 Oct;33(10):2266-70.[Abstract][Full Text]

143. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-81.[Abstract][Full Text]

144. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: preventive medication. Aug 2022 [internet publication].​[Full Text]

145. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002 Nov 15;90(10):1092-7.[Abstract]

146. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010 Mar;12(3):210-8.[Abstract]

147. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-82.[Abstract][Full Text]

148. Turley SD, Dietschy JM. The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Prev Cardiol. Winter 2003;6(1):29-33, 64.[Abstract]

149. Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 Oct;158(2):407-16.[Abstract]

150. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.[Abstract][Full Text]

151. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99.[Abstract][Full Text]

152. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-50.[Abstract]

153. Deedwania P, Murphy SA, Scheen A, et al. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2021 Feb 1;6(2):139-47.[Abstract][Full Text]

154. Backes JM, Gibson CA, Ruisinger JF, et al. Fibrates: what have we learned in the past 40 years? Pharmacotherapy. 2007 Mar;27(3):412-24[Abstract]

155. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002 Dec 9-23;162(22):2597-604.[Abstract]

156. Kim NH, Han KH, Choi J, et al. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019 Sep 27;366:l5125.[Abstract][Full Text]

157. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2002 Dec 9-23;162(22):2597-604.[Abstract]

158. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Feb 29;(3):CD003177.[Abstract][Full Text]

159. Maki KC, Palacios OM, Bell M, et al. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: an updated meta-analysis and review of research gaps. J Clin Lipidol. 2017 Sep-Oct;11(5):1152-60.[Abstract][Full Text]

160. Bernasconi AA, Wiest MM, Lavie CJ, et al. Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials. Mayo Clin Proc. 2021 Feb;96(2):304-13.[Abstract][Full Text]

161. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.[Abstract][Full Text]

162. Ridker PM, Rifai N, MacFadyen J, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation. 2022 Aug 2;146(5):372-9.[Abstract][Full Text]

163. Fazio S, Guyton JR, Lin J, et al. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab. 2010 Nov;12(11):983-93.[Abstract]

164. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003 Jun 15;91(12):1432-6.[Abstract]

165. Pan J, Lin M, Kesala RL, et al. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab. 2002 Jul;4(4):255-61.[Abstract]

166. Bays HE, Shah A, Lin J, et al. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol. 2010 Nov-Dec;4(6):515-21.[Abstract]

167. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013 May;34(17):1279-91.[Abstract][Full Text]

168. Plat J, van Onselen EN, van Heugten MM, et al. Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters. Eur J Clin Nutr. 2000 Sep;54(9):671-7.[Abstract]

169. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.[Abstract][Full Text]

170. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.[Abstract][Full Text]

171. Li SY, Zhao YL, Yang YF, et al. Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: a meta-analysis. Int J Endocrinol. 2020;2020:4732021.[Abstract][Full Text]

172. Anagnostis P, Stevenson JC. Cardiovascular health and the menopause, metabolic health. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101781.[Abstract]

173. Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020 May;158(7):1999-2014.e1.[Abstract][Full Text]

174. Chan WK, Chuah KH, Rajaram RB, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213.[Abstract][Full Text]

175. Liu J, Xu J, Guan S, et al. Effects of different treatments on metabolic syndrome in patients with obstructive sleep apnea: a meta-analysis. Front Med (Lausanne). 2024;11:1354489.[Abstract][Full Text]

176. Cattazzo F, Pengo MF, Giontella A, et al. Effect of continuous positive airway pressure on glucose and lipid profiles in patients with obstructive sleep apnoea: a systematic review and meta-analysis of randomized controlled trials. [in spa]. Arch Bronconeumol. 2023 Jun;59(6):370-6.[Abstract][Full Text]

177. Scurt FG, Ganz MJ, Herzog C, et al. Association of metabolic syndrome and chronic kidney disease. Obes Rev. 2024 Jan;25(1):e13649.[Abstract][Full Text]

178. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 Jul 21;387(3):205-16.[Abstract][Full Text]

179. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011 Jun;13(6):498-504.[Abstract]

180. Anagnostis P, Katsiki N, Adamidou F, et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism. 2013 Jan;62(1):21-33.[Abstract]

181. Olson EJ, Pearce GL, Jones NP, et al. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2289-94.[Abstract][Full Text]

182. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-418.[Abstract][Full Text]

183. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023 Apr 13;388(15):1353-64.[Abstract]

184. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023 Jul 11;330(2):131-40.[Abstract][Full Text]

185. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.[Abstract][Full Text]

186. Gonzalez-Campoy JM, St Jeor ST, Castorino K, et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract. 2013 Sept-Oct;19 Suppl 3:1-82.[Abstract]

187. Grundy SM, Cleeman JI, Mertz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39.[Abstract][Full Text]

188. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017 Apr;23(suppl 2):1-87.[Abstract][Full Text]

189. World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Aug 2021 [internet publication].[Full Text]

190. Park S, Lee S, Kim Y, et al. Altered risk for cardiovascular events with changes in the metabolic syndrome status: a nationwide population-based study of approximately 10 million persons. Ann Intern Med. 2019 Dec 17;171(12):875-84.[Abstract]

191. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16.[Abstract][Full Text]

192. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022 Mar;145(9):e722-59.[Abstract][Full Text]

193. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007 Jan 30;49(4):403-14.[Abstract]

194. Boden-Albala B, Sacco RL, Lee HS, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke. 2008 Jan;39(1):30-5.[Abstract][Full Text]

195. Reinehr T, Wunsch R, Pütter C, et al. Relationship between carotid intima-media thickness and metabolic syndrome in adolescents. J Pediatr. 2013 Aug;163(2):327-32.[Abstract]

196. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006 Mar 21;47(6):1093-100.[Abstract]

197. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008 Sep;31(9):1898-904.[Abstract][Full Text]

198. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007 May;30(5):1219-25.[Abstract][Full Text]

199. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84.[Abstract]

200. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005 Nov 15;143(10):722-8.[Abstract]

201. Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005 Mar 28;11(12):1848-53.[Abstract]

202. Magliano M. Obesity and arthritis. Menopause Int. 2008 Dec;14(4):149-54.[Abstract]

203. Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006 Jul 1;107(1):28-36.[Abstract]

204. Lund Håheim L, Wisløff TF, Holme I, et al. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006 Oct 15;164(8):769-74.[Abstract][Full Text]

205. Pasanisi P, Berrino F, De Petris M, et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006 Jul 1;119(1):236-8.[Abstract]

206. Chavez-Tapia NC, Murúa-Beltrán Gall S, Ordoñez-Vázquez AL, et al. Understanding the role of metabolic syndrome as a risk factor for hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:583-93.[Abstract][Full Text]

207. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 Aug;4(8):579-91.[Abstract]

208. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006 Sep 25;166(17):1871-7.[Abstract][Full Text]

209. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-35.[Abstract][Full Text]

210. Alsuwaidi HN, Ahmed AI, Alkorbi HA, et al. Association between metabolic syndrome and decline in cognitive function: a cross-sectional study. Diabetes Metab Syndr Obes. 2023;16:849-59.[Abstract][Full Text]

211. Qureshi D, Collister J, Allen NE, et al. Association between metabolic syndrome and risk of incident dementia in UK Biobank. Alzheimers Dement. 2024 Jan;20(1):447-58.[Abstract][Full Text]

212. National Institute for Health and Care Excellence. Cardiovascular disease prevention. June 2010 [internet publication].[Full Text]